- Home
- INZY vs EARN Comparison
INZY vs EARN Comparison
Compare INZY & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- EARN
- Stock Information
- Founded
- INZY 2015
- EARN 2012
- Country
- INZY United States
- EARN United States
- Employees
- INZY N/A
- EARN N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- EARN Real Estate Investment Trusts
- Sector
- INZY Health Care
- EARN Real Estate
- Exchange
- INZY Nasdaq
- EARN Nasdaq
- Market Cap
- INZY 188.2M
- EARN 187.6M
- IPO Year
- INZY 2020
- EARN 2013
- Fundamental
- Price
- INZY $1.36
- EARN $6.60
- Analyst Decision
- INZY Strong Buy
- EARN Hold
- Analyst Count
- INZY 8
- EARN 1
- Target Price
- INZY $17.75
- EARN N/A
- AVG Volume (30 Days)
- INZY 1.0M
- EARN 639.2K
- Earning Date
- INZY 03-11-2025
- EARN 03-05-2025
- Dividend Yield
- INZY N/A
- EARN 14.53%
- EPS Growth
- INZY N/A
- EARN 277.67
- EPS
- INZY N/A
- EARN 1.02
- Revenue
- INZY N/A
- EARN N/A
- Revenue This Year
- INZY N/A
- EARN N/A
- Revenue Next Year
- INZY N/A
- EARN $89.08
- P/E Ratio
- INZY N/A
- EARN $6.46
- Revenue Growth
- INZY N/A
- EARN N/A
- 52 Week Low
- INZY $1.24
- EARN $5.54
- 52 Week High
- INZY $7.80
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- EARN 48.80
- Support Level
- INZY $1.35
- EARN $6.53
- Resistance Level
- INZY $1.62
- EARN $6.82
- Average True Range (ATR)
- INZY 0.13
- EARN 0.13
- MACD
- INZY 0.04
- EARN 0.00
- Stochastic Oscillator
- INZY 32.89
- EARN 40.26
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.